Yasuo Sugitani
Chugai Pharmaceutical Co., Ltd. (Japan) · 20 works · 72 citations · h-index 5
Top works
- Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database
- Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation
- Quantitative Preferences for Lung Cancer Treatment from the Patients’ Perspective: A Systematic Review
- Patient Preferences for Attributes of Chemotherapy for Lung Cancer: Discrete Choice Experiment Study in Japan
- Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database
- Biomarker‐based Bayesian randomized clinical trial design for identifying a target population
- Change-point detection using diffusion maps for sleep apnea monitoring with contact-free sensors
- Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
- Comparison of consumer-grade wearable devices with a research-grade instrument for measuring physical activity in a free-living setting
- Postmarketing Benefit-Risk Assessment for Erythropoiesis-Stimulating Agents Using a Health Care Database
- Patient Preference on Age-Related Macular Degeneration Treatment: A Systematic Review
- Effect of the COVID-19 pandemic on outpatient care and rehabilitation in neuromuscular clinical practice in Japan: a health insurance claims database analysis
- Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival
- Identifying Terminologies Used Prior to the Onset of Interstitial Lung Disease in Patients With Lung Cancer: Descriptive Analysis of Electronic Medical Record Data
- Time series monitoring of patient condition using deep learning.
- MO54-5 Assessment of the impact of COVID-19 on malignancy surgeries by interrupted time series analysis using real world data
- MO5-5 Comparison of first-line therapy regimens for non-small cell lung cancer with different Japanese real world data sources
- Abstract 409: Immunofluorescent digital slide technology to evaluate correlation between Glypican-3 expression and response to codrituzumab
- Prediction of prognosis of active vitamin D preparation in patients with hypoparathyroidism using Medical Real World Data
- Analysis of the use of drugs for patients with COVID-19 using graph embedding